Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event. METHODS: 171...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Manag Res
Hauptverfasser: Walter, Robert Fred Henry, Sydow, Saskia Roxanne, Berg, Erika, Kollmeier, Jens, Christoph, Daniel Christian, Christoph, Sandra, Eberhardt, Wilfried Ernst Erich, Mairinger, Thomas, Wohlschlaeger, Jeremias, Schmid, Kurt Werner, Mairinger, Fabian Dominik
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove 2019
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6765394/
https://ncbi.nlm.nih.gov/pubmed/31576173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S194337
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge